When can personal best peak flow be determined for asthma action plans?

Thorax

Volumn 59, Issue 11, 2004, Pages 922-924

  Reddel, H K ^a,b   Marks, G B ^b   Jenkins, C R ^b  

^a Woolcock Inst of Medical Research ^*  (Australia)

^b WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; DISEASE CONTROL; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOMES RESEARCH; PATIENT MONITORING; PEAK EXPIRATORY FLOW; PERSONAL BEST PEAK EXPIRATORY FLOW; PREDICTION; PRIORITY JOURNAL; SELF CARE; SPIROMETRY; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; HUMANS; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; PREDICTIVE VALUE OF TESTS;

EID: 8544256296     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.023077     Document Type: Article

References (13)

1. Gibson PG, Powell H, Coughlan J, et al. Self-management education and regular practitioner review for adults with asthma (Cochrane review). The Cochrane Library. Issue 1. Oxford: Update Software, 2003.
2. National Institutes of Health. National Asthma Education and Prevention Program Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. Bethesda, MD: NHLBI, NIH, 1997.
3. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004;59:94-9.
4. Reddel HK, Jenkins CR, Marks GB, et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000;16:226-35, 579 (erratum).
5. Nunn A, Gregg I. New regression equations for predicting peak expiratory flow in adults. BMJ 1989;298:1068-70.
6. Reddel HK, Ware SI, Salome CM, et al. Pitfalls in processing electronic spirometric data in asthma. Eur Respir J 1998;12:853-8.
7. Wilson DH, Adams RJ, Appleton SL, et al. Prevalence of asthma and asthma action plans in South Australia: population surveys from 1990 to 2001. Med J Aust 2003;178:483-5.
8. Diner B, Brenner B, Camargo CA Jr. Inaccuracy of "personal best" peak expiratory flow rate reported by inner-city patients with acute asthma. J Asthma 2001;38:127-32.
9. Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med 1992;34:507-13.
10. Phillips K, Oborne J, Lewis S, et al. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax 2004;59:26-30.
11. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
12. Reddel H, Ware S, Marks G, et al. Differences between asthma exacerbations and poor asthma control. Lancet 1999;353:364-9, 758 (erratum).
13. Clark T, Bateman E, Boushey H, et al. Time course of achievement of individual clinical goals of asthma treatment: the results of the GOAL study. Am J Respir Crit Care Med 2004;169(Suppl):A318.